BRAF and colorectal carcinoma: Among those clinicopathological parameters, molecular characteristics of CRC including B-raf proto-oncogene, serine/threonine kinase (BRAF), human epidermal growth factor receptor 2 (HER2), microsatellite instability (MSI), and rat sarcoma homolog family (RAS) are important therapy determinants (5, 6).